Kymera Fast Tracked for T-Cell Lymphoma Treatment

 KT-333 Phase 1 oncology trial ongoing with an update including initial evaluation of its clinical antitumor activity in patients expected in the fourth quarter of 2023

Fast Track designation can potentially accelerate KT-333’s development path for the treatment of R/R Cutaneous T-Cell Lymphoma and R/R Peripheral T-Cell Lymphoma

https://www.biospace.com/article/releases/kymera-therapeutics-receives-u-s-fda-fast-track-designation-for-kt-333-a-first-in-class-investigational-stat3-degrader-for-the-treatment-of-relapsed-refractory-cutaneous-t-cell-lymphoma-and-relapsed-refractory-peripheral-t-cell-lymphoma/